🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This stems from revelations that a so-called "milestone" deal on drug pricing, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond vague headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, promoted as a "landmark" achievement, is still an "agreement in principle" without detailed provisions. It has been highlighted that the public statements from the UK and US governments describe the deal in divergent terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"There is a serious risk that the UK government has promised concessions to raise drug prices in return for only a verbal promise from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a tendency for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been amplified by Washington's recent decision to suspend the high-value digital accord, which was previously described as "a huge leap forward" in the bilateral relationship. The US claimed a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions promised for British farmers as part of an initial accord have still not been formally approved by the US, despite a imminent January deadline. "We have been informed that that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have expressed concerns that the government's US-UK accords are flimsy and unreliable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "What is even more astonishing than the administration's tactics is the UK government's credulous faith that his administration is a reliable partner. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the chances of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is a feature of dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have arisen in enacting the initial US-UK accord. Promised quotas on beef exports have failed to be approved, and the commitment to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

Looking ahead, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.